Kausambi Vanijya (BSE Code : 538295) Risky Stock ( Dont Buy)

Kausambi Vanijya (BSE Code : 538295)

With a view to fool hapless small investors, a couple of wily market operators are at again. This time they have started a kite buying exercise to give a boost to the market price of Kausambi Vanijya, a company which boasts of

diversified business activity but mainly deals in stock markets. They aim as at least doubling the share price which is around Rs. 9 SMSs are being sent to hundreds of small investors prompting them to buy as many shares as they can buy from 1 lakh to 1 crore shares as these shares are available, damn cheap. But the ‘advice’ of these experts is ridiculous as even after 20 years, its revenues have not gone beyond Rs. 4 crore and the net profit for the fiscal

2015 is hold your breath Rs. 1 lakh. It is also intriguing to know that in the years ended March 2013, the company has earned a net profit of Rs. 2 lakh on revenues of Rs. 4.14 crore. It is all the more intriguing that while the com-

pany has earned a net profit of Rs. 1 lakh on revenues of Rs. 38 lakh in the fiscal 2013 while it has earned the same net profit of Rs. 1 lakh on revenues of Rs. 4.14 crore in the fiscal 2015. On what basis these operators are recommend-ing’ investors to buy these shares is not known to us. Can investors find out?

Comments

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News* *TCI FINANCE LTD (501242 & NSE) (31)* Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc. The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services. *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share ...

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige...

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such...

Value Research

Search This Blog